CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net income	$ 16,617	$ 28,353	$ 11,681
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	15,778	10,507	5,334
Non-cash interest expense	4,248	3,977	2,274
Stock-based compensation expense	10,192	6,747	4,595
Deferred tax expense	71	(24,679)	(4,092)
Loss on revaluation of contingent consideration	0		3,242
Other	(3)	64	(8)
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	(6,101)	(6,888)	(3,222)
Royalties and other receivables	7	644	(652)
Unbilled receivables	(2,602)
Inventories	(4,042)	605	(6,163)
Prepaid expenses and other assets	(1,769)	(1,304)	612
Accounts payable	2,266	807	(1,802)
Accrued expenses	(1,398)	(1,993)	(4,038)
Long-term liabilities	(494)	611	(240)
Total cash provided by operating activities	32,770	17,451	7,521
Cash flows from investing activities:
Purchases of marketable securities		(47)	(23,700)
Redemption of marketable securities		19,600	23,400
Additions to capitalized software costs	(2,147)
Developed technology intangible asset payment	(1,255)
Proceeds from sale of fixed asset			45
Purchases of property, plant and equipment	(10,635)	(5,454)	(4,325)
Total cash used in investing activities	(14,037)	(98,696)	(49,194)
Cash flows from financing activities:
Proceeds from issuance of senior convertible notes, net of issuance costs			111,070
Proceeds from issuance of common stock, net of issuance costs		129,309
Exercise of stock options	3,418	2,351	1,841
Repayment of senior convertible notes	(11)
Payments of contingent consideration		(1,715)	(798)
Total cash provided by financing activities	3,407	129,945	112,113
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(2,077)	2,376	(2,299)
Net increase in cash, cash equivalents and restricted cash	20,063	51,076	68,141
Cash, cash equivalents and restricted cash, beginning of period	173,759	122,683	54,542
Cash, cash equivalents and restricted cash, end of period	193,822	173,759	122,683
Supplemental disclosure of cash flow information:
Income taxes paid	4,046	4,021	3,993
Interest paid	2,444	2,444	1,222
Supplemental disclosure of non-cash investing and financing activities:
Non-cash effect of adoption of ASU 2016-16	5,609
Payment of contingent consideration in common stock	0	1,063	875
Property, plant and equipment related to lease incentives	2,270
Spectrum Lifesciences Inc.
Cash flows from investing activities:
Acquisition of assets, net of cash acquired		(112,795)
Supplemental disclosure of non-cash investing and financing activities:
Common stock tendered for acquisition of assets	0	$ 247,575
Atoll GmbH
Cash flows from investing activities:
Acquisition of assets, net of cash acquired			(8,767)
Supplemental disclosure of non-cash investing and financing activities:
Common stock tendered for acquisition of assets	0		14,135
TangenX Technology Corporation
Cash flows from investing activities:
Acquisition of assets, net of cash acquired			$ (35,847)